Cure8 news brief
New oral drugs that act mainly in the gut could offer more convenient options and potentially fewer systemic side effects for people with UC or Crohn’s disease. Early clinical signals and a planned Phase 2 trial mean this drug could enter formal testing for IBD in the near term.
Adult patients with ulcerative colitis or Crohn’s disease, clinicians and researchers tracking new oral IBD therapies, and people interested in drug-development news and market positioning.
This Benzinga article is a market/analyst write-up, not a clinical paper. It highlights that PALI-2108 is intended to concentrate active drug in intestinal tissue (ileum and colon) to limit systemic exposure and that early Phase 1 studies reported positive results in UC and fibrostenotic CD.
The company plans a Phase 2 study in Crohn’s disease and expects regulatory filings later in 2026. The story includes analyst sales forecasts and stock movement — these are investment perspectives, not clinical guidance.
If you’re following treatment advances, this is a candidate to watch because it represents a next-generation, intestine-selective PDE4 approach. However, Phase 1 results are preliminary and not proof of safety or effectiveness; larger randomized Phase 2/3 trials are required to define benefit, risks, and place in care.
The article does not provide detailed efficacy or safety data, nor peer-reviewed results.
This is a business/analyst news article summarizing company claims and early-phase trial activity; it reports planned regulatory steps and analyst sales projections. It does not present detailed trial data or peer-reviewed study results. Expectations should be tempered until randomized Phase 2/3 data are published.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
